SOUTH SAN FRANCISCO, Calif., March 15, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that Arthur B. Laffer, Ph.D , has resigned from the Company’s Board of Directors to pursue other longstanding interests, effective immediately. Dr. Laffer has served on the OXiGENE Board of Directors since 1998 and had served as Chair of the Audit Committee, the Chair of the Compensation Committee and a member of the Nominating and Governance Committee.
